Voronezh Regional Clinical Consultative and Diagnostic Center
Who can join
18 and older, any sex, with COVID-19 or Myocardial Injury. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Percentage of Patients (%) Recovered From COVID-19 With a Decrease in the Global Contractility of the Left and Right Ventricles.Primary· Up to 12 months
Decrease of the left ventricle ejection fraction below 57% in men and women or decrease of the right ventricle ejection fraction below 52% in men and 51% in women.
Group
Value
95% CI
Patients Recovered From COVID-19
19
Patients Recovered From COVID-19
39
Patients Recovered From COVID-19
48
Proportion of Patients (%) Recovered From COVID-19 With Signs of Pericardial Effusion.Primary· Up to 12 months
Presence of pericardial effusion, i.e., presence of free echocardiographic spaces between the pericardial layers during diastole with pericardial layer thickness more than 4mm.
Pericardial effusion
Group
Value
95% CI
Patients Recovered From COVID-19
27
No pericardial effusion
Group
Value
95% CI
Patients Recovered From COVID-19
79
Proportion of Patients (%) Recovered From COVID-19 With Signs of Early and Late Gadolinium Enhancement of Myocardium.Primary· Up to 12 months
Presence of early and late gadolinium enhancement of myocardium on cardiac MRI.
Presence of early and late gadolinium enhancement of myocardium.
Group
Value
95% CI
Patients Recovered From COVID-19
28
No early and late gadolinium enhancement of myocardium.
Group
Value
95% CI
Patients Recovered From COVID-19
78
Evaluation of Quality of Life of the Patients Recovered From the COVID-19 by the Duke Activity Status Index.Secondary· At the time of enrollment, but analysis of quality of life criteria was additionally decided to be performed as a separate sub-study.
The Duke Activity Status Index is an assessment tool used to evaluate the functional capacity of patients with cardiovascular disease. Positive responses are summed up to get a total score, which ranges from 0 to 58.2. Higher scores would indicate a higher functional capacity.
Group
Value
95% CI
Patients Recovered From COVID-19
31.8
± 12.3
Sponsor's own description
In this observational study follow-up and dynamic observation will be conducted on the participants recovered from pneumonia caused by COVID-19. The main goal is an early diagnosis and detection of myocardial (heart) injury and quality of life in participants recovered from COVID-19 and follow-up in selected participants with present signs of myocarditis and/or myocardial fibrosis.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults
· Phase 1
· active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
· Phase 3
· active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes
· Phase 1
· recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
· Phase 2
· recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A
· Phase 3
· active not recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Voronezh Regional Clinical Consultative and Diagnostic Center
Last refreshed: 19 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04794062.